Del Mar Pharmaceuticals

OverviewSuggest Edit

DelMar Pharmaceuticals, Inc. engages in developing and commercializing cancer therapies in orphan and other cancer indications for the treatment of patients failing modern targeted or biologic therapy. The Сompany’s principal product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in clinical trials stage for the treatment of refractory glioblastoma multiforme, a form of brain cancer. DelMar Pharmaceuticals, Inc. also has a strategic collaboration with Guangxi Wuzhou Pharmaceutical Company for the development of VAL-083 used in treating chronic myelogenous leukemia and lung cancer. 
TypePublic
Founded2010
HQSan Diego, CA, US
Websitedelmarpharma.com
Overall CultureD

Latest Updates

Employees (est.) (Jun 2019)2(-50%)
Revenue (FY, 2012)$0
Share Price (Jan 2021)$1.9(+2%)
Cybersecurity ratingAMore

Key People/Management at Del Mar Pharmaceuticals

Saiid Zarrabian

Saiid Zarrabian

President and Chief Executive Officer, Director
Scott Praill

Scott Praill

Chief Financial Officer
Lynda Cranston

Lynda Cranston

Director
Dennis M. Brown

Dennis M. Brown

Chief Scientific Officer
John Liatos

John Liatos

Senior Vice President, Business Development, Director
Robert E. Hoffman

Robert E. Hoffman

Chairman of the Board
Show more

Del Mar Pharmaceuticals Office Locations

Del Mar Pharmaceuticals has offices in San Diego, Menlo Park and Vancouver
San Diego, CA, US (HQ)
12707 High Bluff Dr #200
Menlo Park, CA, US
3475 Edison Way r
Vancouver, CA
720-999 W Broadway
Show all (3)

Del Mar Pharmaceuticals Financials and Metrics

Del Mar Pharmaceuticals Revenue

USD

Net income (Q3, 2021)

(6.6m)

Market capitalization (28-Jan-2021)

15.4m

Closing stock price (28-Jan-2021)

1.9

Cash (31-Mar-2021)

15.7m

EV

138.6k
Del Mar Pharmaceuticals's current market capitalization is $15.4 m.
Annual
USDFY, 2012FY, 2015FY, 2017FY, 2018FY, 2019

Revenue

General and administrative expense

7.3k3.3m

R&D expense

5.0m

Operating expense total

7.3k8.3m33.2k60.7k
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q1, 2013Q2, 2013Q3, 2013Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q2, 2021Q3, 2021

Revenue

General and administrative expense

696.04.2k1.4k4.2k920.4k1.7m741.4k445.0k656.2k500.8k474.0k890.7k630.2k1.3m571.3k698.1k744.6k1.0m1.2m986.5k874.9k935.5k913.6k1.1m1.1m2.8m2.8m

R&D expense

631.9k584.4k560.2k671.6k612.2k641.8k603.8k789.2k790.3k732.7k1.1m1.1m1.9m2.1m1.8m1.0m947.2k735.8k721.5k712.2k898.7k2.6m3.8m

Operating expense total

696.04.2k1.4k4.2k1.6m2.2m1.3m1.1m1.3m1.1m1.1m1.7m1.4m2.0m1.7m1.8m2.7m3.2m2.9m2.0m1.8m1.7m1.7m1.8m2.0m5.4m6.6m
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

1.8k4.1m4.8m1.8m6.6m6.0m3.7m2.4m

Accounts Receivable

11.1k

Prepaid Expenses

170.9k234.6k245.0k1.2m1.0m355.6k

Current Assets

7.9m7.0m2.9m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q1, 2013Q2, 2013Q3, 2013Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q2, 2021Q3, 2021

Cash

6.8k805.02.8k609.04.0k7.5m6.3m5.2m4.3m4.0m3.0m2.8m2.0m937.4k4.8m3.4m2.1m13.2m11.0m8.5m3.9m3.7m2.2m8.1m6.3m5.0m17.2m15.7m

Accounts Receivable

13.8k

Prepaid Expenses

83.5k221.3k210.5k162.2k155.9k357.6k191.6k167.5k85.3k177.3k130.8k119.8k1.2m1.1m1.1m831.5k306.7k240.1k223.7k123.0k114.9k551.0k363.0k

Current Assets

3.4m3.0m2.1m1.1m5.0m3.6m2.3m14.4m12.2m9.6m4.7m4.0m2.4m8.4m6.5m5.1m17.7m16.6m
USDQ1, 2012

Financial Leverage

1 x
Show all financial metrics

Del Mar Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Del Mar Pharmaceuticals Online and Social Media Presence

Embed Graph

Del Mar Pharmaceuticals Company Culture

  • Overall Culture

    D

    59/100

  • CEO Rating

    D

    63/100

  • Compensation

    C+

    70/100

Learn more on Comparably

Del Mar Pharmaceuticals Blogs

DelMar Announces $19.6 Million Private Placement Priced At-The-Market

SAN DIEGO, Aug. 18, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company") announced today that it has entered into definitive agreements with investors providing for the sale and issuance of up to 19,587 shares of its Series C Convertible Preferred Stock (the…

DelMar Announces Approval of Merger by Stockholders

SAN DIEGO, Aug. 17, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company") announced today that all proposals related to the proposed merger between DelMar and Adgero were approved by DelMar's stockholders at a special meeting held on August 14, 2020.  The hol…

DelMar Pharmaceuticals to Host Conference Call to Discuss Proposed Acquisition of Adgero Pharmaceuticals

Conference Call to be held Thursday, July 23, 2020 at 4:30pm ET SAN DIEGO, July 17, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies announced today that it will…

DelMar Pharmaceuticals Receives $500,000 Loan from the National Brain Tumor Society and National Foundation for Cancer Research to Support VAL-083's Participation in a Pivotal Study for Glioblastoma Sponsored by the Global Coalition for Adaptive Research

SAN DIEGO, June 24, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies announced today it has received a $500,000 loan from the National Brain Tumor Society (NBTS) …

DelMar Pharmaceuticals Presents Positive Interim Data on VAL-083 Demonstrating Favorable Outcomes in Both Newly- Diagnosed and Recurrent GBM at the AACR Virtual Annual Meeting II

Findings Support Commencement of VAL-083's Participation in Pivotal GCAR GBM AGILE Study SAN DIEGO, June 22, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies…

DelMar to Acquire Adgero Biopharmaceuticals, Expands Late-Stage Oncology Pipeline

Combination creates a diversified biopharmaceutical company with a robust product pipeline targeting rare, unmet medical needs in oncology Pipeline led by two late-stage, Phase 3-ready cancer therapeutics - VAL-083 for glioblastoma multiforme (GBM) and REM-001 for cutaneous metastatic breast cancer …
Show more

Del Mar Pharmaceuticals Frequently Asked Questions

  • When was Del Mar Pharmaceuticals founded?

    Del Mar Pharmaceuticals was founded in 2010.

  • Who are Del Mar Pharmaceuticals key executives?

    Del Mar Pharmaceuticals's key executives are Saiid Zarrabian, Scott Praill and Lynda Cranston.

  • How many employees does Del Mar Pharmaceuticals have?

    Del Mar Pharmaceuticals has 2 employees.

  • Who are Del Mar Pharmaceuticals competitors?

    Competitors of Del Mar Pharmaceuticals include Kyowa Kirin, Takeda Oncology and Ethypharm.

  • Where is Del Mar Pharmaceuticals headquarters?

    Del Mar Pharmaceuticals headquarters is located at 12707 High Bluff Dr #200, San Diego.

  • Where are Del Mar Pharmaceuticals offices?

    Del Mar Pharmaceuticals has offices in San Diego, Menlo Park and Vancouver.

  • How many offices does Del Mar Pharmaceuticals have?

    Del Mar Pharmaceuticals has 3 offices.